<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Moleculin Biotech, Inc.

    Moleculin Biotech, Inc.

    Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the ...

    Moleculin Biotech, Inc. is a clinical stage pha...

    Filing Type:    PU
    Precipio, Inc.

    Precipio, Inc.

    Precipio has built a platform designed to eradicate the problem of misdiagnosis by...

    Precipio has built a platform designed to eradi...

    Filing Type:    PU
    Lonza Group AG

    Lonza Group AG

    Lonza is an integrated solutions provider that creates value along the Healthcare ...

    Lonza is an integrated solutions provider that ...

    Filing Type:    PU
    BioLife Solutions, Inc.

    BioLife Solutions, Inc.

    BioLife Solutions is the leading developer, manufacturer and supplier of proprieta...

    BioLife Solutions is the leading developer, man...

    Filing Type:    PU
    iCAD inc.

    iCAD inc.

    iCAD, Inc. an industry-leading provider of advanced image analysis, workflow solut...

    iCAD, Inc. an industry-leading provider of adva...

    Filing Type:    PU
    Precision BioSciences, Inc.

    Precision BioSciences, Inc.

    Precision BioSciences is dedicated to improving life (DTIL) through its proprietar...

    Precision BioSciences is dedicated to improving...

    Filing Type:    PU
    Neoleukin Therapeutics, Inc.

    Neoleukin Therapeutics, Inc.

    Neoleukin is a biopharmaceutical company creating next generation immunotherapies ...

    Neoleukin is a biopharmaceutical company creati...

    Filing Type:    PU
    Precision BioSciences, Inc.

    Precision BioSciences, Inc.

    Precision BioSciences is dedicated to improving life (DTIL) through its proprietar...

    Precision BioSciences is dedicated to improving...

    Filing Type:    PU
    Replimune Group, Inc.

    Replimune Group, Inc.

    Cancer is one of the most difficult diseases to treat. It is constantly changing, ...

    Cancer is one of the most difficult diseases to...

    Filing Type:    PU
    Spectrum Pharmaceuticals, Inc.

    Spectrum Pharmaceuticals, Inc.

    Spectrum Pharmaceuticals is a leading biotechnology company with a focus in Oncolo...

    Spectrum Pharmaceuticals is a leading biotechno...

    Filing Type:    PU
    Adaptive Biotechnologies Corporation

    Adaptive Biotechnologies Corporation

    We are a commercial-stage biotech company focused on harnessing the inherent biolo...

    We are a commercial-stage biotech company focus...

    Filing Type:    PU
    ViewRay, Inc.

    ViewRay, Inc.

    ViewRayÂŽ Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdianÂŽ the wor...

    ViewRayÂŽ Inc., (NASDAQ:VRAY), designs, manufac...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.